kindlin1 inhibitor

Kindlin1 inhibitors are a class of therapeutic agents targeting FERMT1 (Kindlin-1), a focal adhesion protein involved in integrin activation and signaling. Research presented at AACR 2026 by Hoshi University identifies Kindlin1 as a synthetic lethal target in gastrointestinal cancers where its paralogs, Kindlin2 (FERMT2) and Kindlin3 (FERMT3), are silenced by DNA methylation. Mechanistically, the suppression of Kindlin1 in these specific genetic backgrounds leads to severe adhesion deficiency and the inactivation of the YAP signaling pathway through its translocation from the nucleus to the cytosol, independent of its phosphorylation status. Preclinical studies using inducible knockdown models have demonstrated tumor regression in gastrointestinal cancer xenografts, suggesting that Kindlin1 inhibition is a viable therapeutic strategy for the subset of gastrointestinal cancers exhibiting Kindlin2 and Kindlin3 methylation.

Other names

kindlin1 inhibitorkindlin-1 inhibitorkindlin 1 inhibitorFERMT1 inhibitorFERMT-1 inhibitorFERMT 1 inhibitor